AREBP Inhibitors
AREBP inhibitors encompass a range of chemical compounds that exert their inhibitory effects by interfering with various signaling pathways and cellular processes essential for AREBP function. Rapamycin, for instance, suppresses the mTOR pathway, a key regulator of protein synthesis, resulting in decreased synthesis and availability of AREBP within the cell. Similarly, LY 294002, by inhibiting PI3K, disrupts AKT signaling, leading to a reduction in the pathways that enhance AREBP's activity, thereby diminishing its function. Erlotinib, as an EGFR tyrosine kinase inhibitor, blocks the EGFR signaling cascade, which is crucial for maintaining cellular processes that support AREBP's role, indirectly leading to its functional diminishment. Other inhibitors like WZ8040 and PD 98059 target kinases such as NUAK1 and MEK respectively, which are instrumental in cellular metabolism and division, thus indirectly reducing AREBP's activity by altering the cellular environment and signaling context necessary for its optimal function.
Complementing these mechanisms are inhibitors that target stress response and inflammation pathways, such as SB203580 and SP600125, which specifically inhibit p38 MAPK and JNK, leading to subdued cellular support for AREBP's activity. Bortezomib, by inhibiting proteasome activity, induces a stress response that hampers overall protein function, affecting AREBP by extension. Kinase inhibitors like Sorafenib and Sunitinib, through broad-spectrum kinase inhibition, including that of RAF, VEGF, and PDGF receptors, indirectly diminish AREBP's activity by disrupting critical survival and angiogenesis signaling pathways. Lastly, U0126 and Gefitinib, by selectively inhibiting MEK enzymes and the EGFR pathway, reduce ERK signaling and block EGFR-dependent cellular processes, respectively, which are essential for the regulation of proliferation and survival where AREBP's functional activity is consequentially diminished. Each inhibitor, through its unique interaction with cellular signaling, contributes to the collective inhibition of AREBP, revealing the intricate web of regulatory pathways that govern its activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin selectively inhibits mTOR (mammalian target of rapamycin), which is a critical regulator of protein synthesis and cell growth. The inhibition of mTOR leads to reduced protein synthesis, which can diminish the functional activity of AREBP by limiting its availability in the cell. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a potent inhibitor of PI3K (phosphoinositide 3-kinases). PI3K signaling is crucial for the activation of downstream pathways like AKT, which can affect a variety of cellular processes including protein synthesis. Inhibiting PI3K can lead to reduced activity of AKT, indirectly diminishing the function of AREBP by impairing the pathways that facilitate its activity. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is an EGFR tyrosine kinase inhibitor, disrupting the EGFR signaling pathway. As EGFR is involved in the regulation of various cellular processes, including cell proliferation and survival, its inhibition can indirectly diminish the functional activity of AREBP by reducing the signaling that sustains its function. | ||||||
WZ8040 | 1214265-57-2 | sc-364656 sc-364656A | 5 mg 10 mg | $255.00 $480.00 | ||
WZ8040 is a selective NUAK1 kinase inhibitor. NUAK1, also known as AMPK-related kinase, can influence cellular metabolism and energy homeostasis. Inhibiting NUAK1 can lead to altered metabolic states that may indirectly diminish the functional activity of AREBP by affecting the energetic environment it requires for its activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a selective MEK inhibitor that interferes with the MAPK/ERK pathway. The MAPK/ERK pathway is involved in the regulation of cell division and differentiation. By inhibiting MEK, PD98059 can indirectly lead to the diminished functional activity of AREBP by impeding pathways that contribute to its cellular context and activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a specific inhibitor of p38 MAPK. The p38 MAPK pathway is implicated in stress responses and inflammation. Inhibition of p38 MAPK by SB 203580 can lead to a decrease in the activity of pathways that support cell survival and proliferation, which can indirectly diminish the functional activity of AREBP. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK (c-Jun N-terminal kinases), which are involved in the regulation of apoptosis, cell proliferation, and differentiation. By inhibiting JNK, SP600125 can indirectly lead to the diminished functional activity of AREBP by altering the signaling pathways that regulate its context and function. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can lead to the accumulation of misfolded proteins and disrupt cellular homeostasis. By inhibiting the proteasome, Bortezomib can indirectly diminish the functional activity of AREBP by causing a general stress response that negatively affects protein synthesis and function. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multi-kinase inhibitor that targets RAF kinases, VEGF receptors, and PDGF receptors, among others. By inhibiting these kinases, Sorafenib can indirectly diminish the functional activity of AREBP by modulating the signaling pathways that regulate cell proliferation, survival, and angiogenesis. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is an inhibitor of receptor tyrosine kinases, including PDGF receptors and VEGF receptors. Its inhibition of these receptors can lead to a decrease in signaling pathways critical for cell survival and angiogenesis, thus indirectly diminishing the functional activity of AREBP. | ||||||